Inicio>>Signaling Pathways>> Others>>EC330

EC330

Catalog No.GC32756

EC330 es un inhibidor del factor inhibidor de la leucemia (LIF).

Products are for research use only. Not for human use. We do not sell to patients.

EC330 Chemical Structure

Cas No.: 2016795-77-8

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
275,00 $
Disponible
1mg
90,00 $
Disponible
5mg
270,00 $
Disponible
10mg
387,00 $
Disponible
50mg
1.080,00 $
Disponible
100mg
1.618,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

EC330 is a leukemia inhibitory factor (LIF) inhibitor.

EC330 shows marked specificity in MCF-7 cells overexpressing LIF verses MCF-7 cells. EC330 further shows cytoskeletal disruption and targeting cancer-associated fibroblasts (CAFs) through inhibition of alpha-SMA but not beta-tubulin[1].

EC330 treatment (0.1, 0.5 and 2.5 mg/kg) dose dependently reduces tumor burden in ovarian (IGROV-1) and triple negative breast cancer (MDA-MB-231) cell xenografted mouse models as well as MDA-MB-231 PDX models. EC330 exhibits no reactivity towards thiol-cysteine residues, no off target binding to major receptors, kinases or ion channels. EC330 is orally bioavailable and found to be safe and tolerable in toxicity studies[1].

[1]. Nair HB, et al. Discovery and preclinical pharmacology of EC330: A first-in-class leukemia inhibitory factor (LIF) inhibitor

Reseñas

Review for EC330

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for EC330

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.